Index

Note: Page numbers of article titles are in **boldface** type.

ABDOMINAL pain in hyperlipoproteinaemia (HLP) type V, 21–22
Acanthocytosis, 132–134
Alpha lipoprotein deficiency, familial (Tangier disease), 137–140
  basic defect and plasma lipoprotein pattern, 138
  clinical features and pathogenesis of lesions, 139
  diagnosis, 140
  genetics, 138
  treatment and prognosis, 140
Anaemia, chronic, and lipoproteins, 144
Apolipoproteins, function of the, 20–21

CARBOHYDRATE intake, effects of in type IV HLP, 56–57
Cardiovascular manifestations in familial hyperbetalipoproteinaemia, 91–92
Cerebrovascular disease, 50
Cholestyramine, in treatment of primary type II HLP, 101–102
Chylomicron metabolism, 73–74
Chylomicrons, 4–5, 17–18
Clofibrate, 60
  in treatment of primary type II HLP, 103
Colestipol, in treatment of primary type II HLP, 101–102
Coronary artery disease, 48–49

DEAE-Sephadex, in treatment of primary type II HLP, 101–102
Dietary therapy in HLP—
  type II, 99–101
  type III, 116–117
  type IV, 59–60
Drug therapy in HLP—
  type II, 101–103
  type IV, 60–62

ELECTROPHORESIS, role of in diagnosis of HLP, 8–9
Enzyme defect in HLP type I, 74–75

FAT, malabsorption of—
  in lipoprotein deficiency, 130–132
  in lipoprotein disorders, 143

GENETICS—
  of familial lecithin–cholesterol acyltransferase deficiency, 141
  of FH, 92–95, 137
  of HLP type III, 117
  of HLP type IV, 47–48
Glucose intolerance in HLP type V, 23
Glyceride transport, normal, in HLP type IV, 52–54.

HEPATIC disorders and lipoproteins, 143–144
Heterozygous child, management of in FH, 104–105
Homozygous child, management of in FH, 104
Hyperbetalipoproteinaemia, familial (FH), 88–98
  clinical features, 88–92
  detection of children with, 105–106
  diagnosis, 95–96
  genetics, 92–95
  paediatric aspects of, 103–107
  pedigree of family with, 106–107
  treatment of family with, 106–107
  treatment of children with, 105
  underlying defect in, 96–98
Hyperlipoproteinaemia, 5–10
  differential diagnosis of, 87
  distinguishing type I from type V, 78
  ileal by-pass in treatment of. 103
  lipoproteins and, **3–10**
  treatment of, 9–10
Hyperlipoproteinaemia type I, **73–80**
  clinical characteristics, 75–76
  secondary, 78
  treatment, 79–80

Hyperlipoproteinaemia type II, **81–107**
causes of, 87–88
detection of pattern of, 85–87
primary, 88
treatment of, 98–103
secondary, 87
variability of plasma beta lipoprotein concentration, 81–85
Hyperlipoproteinaemia type IIa, diagnosis of, 86
Hyperlipoproteinaemia type IIb, diagnosis of, 87
Hyperlipoproteinaemia type III, **111–124**
autopsy findings, 119
clinical features, 114–119
diagnosis, 119–120
pathogenesis, 120–122
treatment, 123
Hyperlipoproteinaemia type IV, **41–62**
biochemical defect in, 54–56
clinical manifestations, 48–52
diagnosis, 43–47
family studies, 47
genetics, 47–48
history, 41–43
paediatric type, 47–48
phenotypes, 47
relationships to other types, 48
treatment, 59–61
Hyperlipoproteinaemia type V, **11–35**
case histories, 34–35
clinical findings, 21–24
diagnosis, 24–26
diet, 31–33
drugs for, 33
lipoprotein structural defect, 30
pathophysiology and possible mechanisms of, 26–30
primary *v.* secondary, 26–27
regulation of the synthesis and catabolism of triglyceride, 27–30
therapy for, 31–33
Hyperthyroidism and lipoprotein deficiency, 143
Hyperuricaemia, 24, 51–52
Hypobetalipoproteinaemia, familial (FH), 136–137
basic defect and plasma lipoprotein pattern, 137
clinical features, 137
diagnosis, 137
genetics, 137
treatment and prognosis, 137

INSULIN—
in type IV HLP, 57–58
in type V HLP, 23
Insulin (*continued*)
Ischaemic heart disease, HLP type II pattern in, 92

LECITHIN–CHOLESTEROL acyltransferase deficiency, familial, 140–142
basic defect and plasma lipoprotein pattern, 141
clinical features and pathogenesis of lesions, 141–142
diagnosis, 142
genetics, 141
treatment and prognosis, 142
Lipaemia retinalis, in HLP type I, 77
Lipid analysis in diagnosing HLP type IV, 44–45
Lipid composition and morphological features of xanthomas, 117–119
Lipoprotein deficiency—
clinical features and pathogenesis of lesions, 130–135
diagnosis, 135
primary disorders, 127–143
prognosis, 136–137
treatment, 136
Lipoprotein deficiency disorders, **127–144**
Lipoprotein disorders, secondary, 143–144
Lipoproteins, 11–21
and hyperlipoproteinaemia, **3–10**
functions of, 143
metabolism and structural interconversions, 19–21
very low density (VLDL), 14–16

METABOLIC aberrations in type III HLP, 115–116
Metabolism of lipoproteins, 19–21

NEUROPATHY, 134
Nicotinic acid, 61
in treatment of primary type II HLP, 102–103

PANCREATITIS, in HPL type V, 21–22
Pancreatitis, acute, in HPL type IV, 51
Peripheral vascular disease, 48–49
Phenocopies of type IV HLP, 45–47
Plasma, standing, in diagnosis of HLP type IV, 43–44
Plasma beta lipoprotein concentration—
normal range, 83–85
variability of, 81–85
Plasma lipid and lipoproteins in HLP type III, 111–114

Plasma lipoprotein pattern in lipoprotein deficiency, 128–130
Populations and individuals, variability of plasma beta lipoprotein concentrations, 82–83

RETINOPATHY, 134

SCREENING for HLP, 5–8

TANGIER disease (*see* Alpha lipoprotein deficiency, familial)

VASCULAR disease—
in HLP type III, 115
premature, clinical manifestations of type IV HLP, 48–50
premature, in type V HLP, 24
VLDL lipoproteins, 14–16
VLDL metabolism in type IV HLP, 52–58

XANTHOMAS—
in type I HLP, 76–77
in type III HLP, 117–119
in type IV HLP, 50–51
in type V HLP, 23
Xanthomatosis in type IV HLP, 115
Xanthomatous lesions in FH, 89–91

Index

Note: Page numbers of chapter titles are in **boldface** type

ADIPOSE tissue, volume of, in the marrow, 244
Age, and skeletal measurements, 217–218
Ageing and osteoporosis, in particular spinal osteoporosis, **187–200**
Ageing skeleton, distribution of osteoporotic changes in, **203–219**
Ash weight of vertebral samples, 210

BACKACHE, relief of, 175
Biopsy, for osteoporosis, 167–169.
Body weight, total, and skeletal measurements, 217
Bone—
  absolute volume of in physiological senile osteopenia and osteoporosis, 245–249
  amount of in skeleton, 187–192
  excessive loss of, 192
  histological changes in, 333–334
  osteoblastic formation of, 280–281
  osteoclastic resorption of, 280
  physiological senile involution and pathological rarefaction of, **239–255**
  x-ray changes in, 334–339
Bone densitometry, and osteoporosis of spinal column, 173
Bone density—
  changes in, resulting from therapy, 349–351
  of intact vertebral body, 175
Bone dynamics, 265–267
Bone formation and resorption, 285–288
Bone histology, 295, 299–300
Bone loss, osteoporosis and, 265
Bone mass, spinal, and high calcium intake, 174
Bone tissue rarefaction, age and sex differences, 253–254
Bone turnover, 296, 305–307, 339–341
  and corticosteroid osteoporosis, 363
  effect of antithyroid drugs on, 346–347
Bones—
  fracture of long, 193–195
  methods of studying for osteoporotic changes, 204–207
Braces, spinal, 170

CALCANEUS, study of samples of, 216
Calcitonin, in treatment of osteoporosis, 323–324
Calcium—
  dietary, and long bone fractures, 180–181
  high intake, and spinal bone mass, 174
  urinary, 303–305
Calcium absorption, biochemical means of measuring, 281
Calcium balance, 296, 303
  and absorption, 281–285
  and corticosteroid osteoporosis, 363
  in hyperthyroidism, 344–345
Calcium metabolism, hyperthyroidism and, **333–352**
Calcium supplements, for crush fracture patients, 312
Cancellous bone, relative osteoid volume of, 243
  in physiological senile osteopenia, and osteoporosis, 249
Childbearing, osteoporosis and, 171
Clinical log, 171
Corsets, 170
Corticosteroid osteoporosis, **355–367**
  calcium balance and bone turnover, 363
  histology, 361–362
  plasma and urine biochemistry, 362–363
  radiocalcium absorption, 363
  results of radiology, 357–361
  vitamin D treatment, 364
Crush fracture syndrome in postmenopausal women, **293–314**
  bone histology, 295, 299–300
  radiology, 293–295, 297–299
  treatment, 307–309

DEFORMITY, in osteoporosis, 160–166
Diet, and osteoporotics, 174
Dietary calcium, and long bone fractures, 180–181
Diphosphates, in treatment of osteoporosis, 322–323
Dowager's hump, relationship between, and compression fracture, 175

Drugs—
and osteoporotics, 174
effects of antithyroid, 346–349

ENVELOPES, of skeleton, and osteoporosis, 264–265
Exercises, for osteoporotics, 170

FEMUR, upper end of, study of samples, 214
Fluoride, in treatment of osteoporosis, 324–326
Fracture—
and diagnosis of osteoporosis, 173
as diagnostic sign, 166–167
compression, relationship between and Dowager's hump, 175
first, and osteoporosis, 172
prevention of, 170
site of in spinal osteoporosis, 178
Fractures—
and skeletal measurements, relationships between, 218–219
identification and classification of, 223
of long bones, 193–195
and dietary calcium, 180–181

GAMMA-RAY scintography, 167

HEREDITY, and postmenopausal osteoporosis, 171–172
Hormone—
sex, and postmenopausal women, 173, 174
synthetic anabolic, in treatment of osteoporosis, 322
thyroid, mechanism of action, 345
Hyperthyroidism—
and calcium metabolism, **333–352**
changes in plasma, urinary calcium, and phosphorus in, 342–343
results of therapy, 346–352

ILIAC crest, bone study of samples, 210–213
Involution, physiological senile, and pathological rarefaction of bone, **239–255**

LACUNAE—
mean volume of periosteocytic, 244
size of periosteocytic, in controls and osteoporotics, 251
Lumbar vertebral strength of bone, 207–210

MARROW adipose tissue—
changes in volume with age and osteoporosis, 251–252
volume of, 244
Menopause, relationship with spinal osteoporosis, 181–182

OESTROGENS—
in postmenopausal women, 309–311
in treatment of osteoporosis, 321–322
urinary, 295, 300
Orthopaedic management of osteoporosis in postmenopausal women, **159–175**
Osteoid, mineralisation of, 281
Osteopenia, physiological senile, 239–255
Osteopenia and osteoporosis—
absolute volume of spongy bone in physiological senile, 245–249
relative osteoid volume of cancellous bone in physiological senile, 249
trabecula osteoclastic resorption surfaces in physiological senile, 249–251
Osteoporosis—
aetiology, 269–270
ageing and, 187–200
anatomical locus, 269–270
bone loss and, 265
as a pathological skeletal state, 257
changes in volume of marrow adipose tissue with age and, 251–252
clinical syndromes of, 193–199
corticosteroid, *see* Corticosteroid osteoporosis
definition, 171
implications for treatment of, 199–200
in postmenopausal women, orthopaedic management of, **159–175**
measurement of progression of, 172
mechanisms of, 183–185
prognosis in, 172
questions about, 171–175
signs of remission and, 175
skeletal envelopes and, 264–265
spinal, *see* Spinal osteoporosis; Spinal osteoporosis, the syndrome of
studies evaluating treatment, 329–340
studies on pathogenesis of, 326–328
studies on pathogenesis and treatment in postmenopausal and senile, **317–330**
surgical measures, 170
testosterone therapy and, 174
the disease, 257–258
therapy, 270–274
vertebral features in, 264–269
young adult, **277–291**
Osteoporotic changes in the ageing skeleton, distribution of, **203–219**
Osteoporotic deformity, 160–166

Osteoporotic vertebral fractures, amount and quality of trabecular bone in, **221–237**
Osteoporotic women, height and weight of, 178–179
Osteoporotics—
and daily tasks, 173
and diet, 174
and drugs, 174
corsets and braces for, 170
exercises for, 170, 173
health education for, 170–171

PAIN—
in spinal osteoporosis, 177–178
management of in osteoporosis, 169
Pathogenesis of oestrogens, studies on, 326–328
Plasma and urine biochemistry, 295, 300
Plasma calcitonin, and thyroid disease, 352
Plasma calcium changes in hyperthyroidism, 342
Plasma phosphorus changes in hyperthyroidism, 342, 343
Postmenopausal women—
and vitamin D, 175
crush fracture syndrome in, **293–314**
sex hormones and, 173, 174

RADIOCALCIUM absorption, 295, 300–303
Radiogrammetry, 179–180
Radioiodine therapy, effects in hyperthyroidism, 347–349
Radiology, 293–295, 297–299
Radius—
study of samples, 217
x-ray densitometry technique for distal, 205–207
Remodelling period—
clinical factors in osteoporosis, 267–269
turnover rate and drug responsiveness, 273–274
Resorption parameters, and age, 254–255

SERUM calcium, effect of antithyroid drugs on, 346
Skeletal balance, 288–289
Skeletal measurements—
age and, 217–218
relationships between fractures and, 218–219
total body weight and, 217
Skeletal remodelling, histological measurement of, 278–280
Skeleton, amount of bone in, 187–192
Spinal osteoporosis, **257–274**
ageing and, 187–200
and bone densitometry, 173
clinical syndromes of, 195–199
differential diagnosis, 183
in men, 182–183
pain in, 177–178
relationship with the menopause, 181–182
symptoms, 177
the syndrome of, **177–185**

TESTOSTERONE therapy, and osteoporosis, 174
Thyroid hormone, mechanism of action, 345
Thyroid surgery, effects of on calcium metabolism, 347
Trabecular bone—
absolute volume of, 242–243
amount and quality of, in osteoporotic vertebral fractures, **221–237**
analysis of data on, 224–225
concentration, 226–228
concentration measurements, 223
in osteoporotic vertebral fractures (discussion), 234–237
x-ray measurements of, 222
Trabecular osteoclastic resorption surfaces, 244, 249–251

ULNA, study of samples of, 216
Urinary calcium, 303–305
changes in hyperthyroidism, 342–343

VAGINAL smears, 295, 300
Vertebral ageing—
biochemistry of, 262–263
features of normal, 258–263
pattern of normal bone loss, 260–261
remodelling period (sigma), 262, 267
turnover of resorption and bone formation, 261–262
Vertebral bodies—
calculated parameters, 223–224
clinical and pathological data, 223
Vertebral bone, load/g of ash/cm length, 228–230
Vertebral fracture—
amount and quality of trabecular bone in osteoporitics, **221–237**
biconcavity and, 231
Vitamin D, and postmenopausal women, 175

X-RAY densitometry, technique for distal radius, 205–207
X-ray measurements of trabecular bone, 222